Cough - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 96 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cough - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Cough - Pipeline Review, H2 2016', provides an overview of the Cough pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cough and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cough
- The report reviews pipeline therapeutics for Cough by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Cough therapeutics and enlists all their major and minor projects
- The report assesses Cough therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Cough

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Cough
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cough pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cough Overview 9
Therapeutics Development 10
Pipeline Products for Cough - Overview 10
Pipeline Products for Cough - Comparative Analysis 11
Cough - Therapeutics under Development by Companies 12
Cough - Therapeutics under Investigation by Universities/Institutes 14
Cough - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Cough - Products under Development by Companies 19
Cough - Products under Investigation by Universities/Institutes 20
Cough - Companies Involved in Therapeutics Development 21
Afferent Pharmaceuticals, Inc. 21
Alitair Pharmaceuticals, Inc. 22
Alveonix AG 23
AstraZeneca Plc 24
AusBio Ltd 25
Charleston Laboratories, Inc. 26
Conrig Pharma ApS 27
Daewoong Pharmaceutical Co., Ltd. 28
GlaxoSmithKline Plc 29
Glenmark Pharmaceuticals Ltd. 30
GW Pharmaceuticals Plc 31
Hyundai Pharmaceutical Co., Ltd. 32
Johnson & Johnson 33
NeRRe Therapeutics Ltd 34
Orbis Biosciences Inc 35
Patara Pharma, Inc. 36
Pila Pharma AB 37
Vernalis Plc 38
Cough - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Target 41
Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 48
Ax-8 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
benzonatate - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
CCP-05 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
CCP-06 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
CCP-07 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
CCP-08 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
CLAT-313 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
codeine + guaifenesin - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
cromolyn sodium - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
DWJ-1340 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
GRC-17536 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
GSK-2339345 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
guaifenesin + hydrocodone - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
guaifenesin ER - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
JNJ-39729209 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
lesogaberan - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
levodropropizine CR - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
MD-990 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
MK-7264 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
NEO-5937 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
orvepitant maleate - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
S-1226 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Small Molecule to Antagonize TRPA-1 for Pain And Respiratory Disorders - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Small Molecules to Agonize CB1 and CB2 for Chronic Cough and Inflammatory Skin Diseases - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
ST-015 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
XEND-0501 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
Cough - Dormant Projects 81
Cough - Discontinued Products 84
Cough - Product Development Milestones 85
Featured News & Press Releases 85
Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study 85
May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference 85
May 03, 2016: Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors 87
Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference 88
Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study 88
Apr 13, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Single-Dose Comparative Bioavailability Study 88
Dec 21, 2015: Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study 89
Oct 12, 2015: Vernalis announces start of CCP-08 12 month stability testing 89
Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial 90
Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine 91
Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing 91
Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet 91
Sep 09, 2014: Charleston Laboratories Announces Key Clinical Updates for Novel Drug 93
Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 93
Apr 29, 2014: Second Product in Vernalis' Cough Cold Pipeline Achieves Proof-of-Concept 93
Appendix 95
Methodology 95
Coverage 95
Secondary Research 95
Primary Research 95
Expert Panel Validation 95
Contact Us 95
Disclaimer 96

List of Tables

Number of Products under Development for Cough, H2 2016 10
Number of Products under Development for Cough - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Comparative Analysis by Unknown Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Investigation by Universities/Institutes, H2 2016 20
Cough - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016 21
Cough - Pipeline by Alitair Pharmaceuticals, Inc., H2 2016 22
Cough - Pipeline by Alveonix AG, H2 2016 23
Cough - Pipeline by AstraZeneca Plc, H2 2016 24
Cough - Pipeline by AusBio Ltd, H2 2016 25
Cough - Pipeline by Charleston Laboratories, Inc., H2 2016 26
Cough - Pipeline by Conrig Pharma ApS, H2 2016 27
Cough - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 28
Cough - Pipeline by GlaxoSmithKline Plc, H2 2016 29
Cough - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 30
Cough - Pipeline by GW Pharmaceuticals Plc, H2 2016 31
Cough - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 32
Cough - Pipeline by Johnson & Johnson, H2 2016 33
Cough - Pipeline by NeRRe Therapeutics Ltd, H2 2016 34
Cough - Pipeline by Orbis Biosciences Inc, H2 2016 35
Cough - Pipeline by Patara Pharma, Inc., H2 2016 36
Cough - Pipeline by Pila Pharma AB, H2 2016 37
Cough - Pipeline by Vernalis Plc, H2 2016 38
Assessment by Monotherapy Products, H2 2016 39
Assessment by Combination Products, H2 2016 40
Number of Products by Stage and Target, H2 2016 42
Number of Products by Stage and Mechanism of Action, H2 2016 44
Number of Products by Stage and Route of Administration, H2 2016 46
Number of Products by Stage and Molecule Type, H2 2016 47
Cough - Dormant Projects, H2 2016 81
Cough - Dormant Projects (Contd..1), H2 2016 82
Cough - Dormant Projects (Contd..2), H2 2016 83
Cough - Discontinued Products, H2 2016 84